Uprifosbuvir

DB15206InvestigationalSmall molecule

Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and...

Mechanism: Pharmacologically active on RNA-directed RNA polymerase
Curator reviewed
Formula / weight: C₂₂H₂₉ClN₃O₉P · 545.91 g/mol (avg)
Code names: MK-3682

Resolves to

Compound

UNIIJW31KPS26SCAS1496551-77-9ChEMBLCHEMBL3833371

Structure

InChIKeySFPFZQKYPOWCSI-KHFYHRBSSA-NSMILESCC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(Cl)[C@@H]1O)OC1=CC=CC=C1

Targets

O39930NS5b

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Uprifosbuvir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account